Loading viewer...
investor_presentation
Format: PDF investor_presentation
Verona Pharma presents its pipeline for developing innovative respiratory disease therapies, focusing on Ohtuvayre for COPD treatment. The company maintains a strong financial position with $404.6M in cash and equivalents as of June 2024, supported by debt facilities providing future draws up to $425M. The presentation outlines commercialization strategies and market positioning for its lead therapeutic candidate.
investor_presentation
27 Pages
investor_presentation
33 Pages
Vedanta Resources
investor_presentation
NervGen